<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2402221763
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LERCADIP 20 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LERCANIDIPINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        71.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Algorithm SAL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Algorithm SAL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Algorithm SAL
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C08CA13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lercadip belongs to a group of medicines called Calcium Channel Blockers (dihydropyridine derivatives). Lercadip is used to treat high blood pressure also known as hypertension in adults over the age of 18 years (it is not recommended for children under 18 years old).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>D</strong><strong>o not take Lercadip and tell your doctor if:</strong></p><p>&bull; You are allergic (hypersensitive) to lercanidipine hydrochloride or to any other ingredients of Lercadip tablets</p><p>&bull; You have had allergic reactions to drugs closely related to Lercadip tablets (such as amlodipine, nicardipine, felodipine, isradipine, nifedipine or lacidipine)</p><p>&bull; If you are suffering from certain heart diseases:</p><p>&nbsp;&nbsp;&nbsp; - Untreated heart failure</p><p>&nbsp;&nbsp;&nbsp; - Obstruction to flow of blood from the heart</p><p>&nbsp;&nbsp;&nbsp; - Unstable angina (angina at rest or progressively increasing)</p><p>&nbsp;&nbsp;&nbsp; - Within one month of heart attack</p><p>&bull; You have severe liver or kidney problems</p><p>&bull; You are taking drugs that are inhibitors of CYP3A4 isoen&nbsp;</p><p>&nbsp;&nbsp; zyme:</p><p>&nbsp;&nbsp;&nbsp;&nbsp; - Antifungal medicines (such as ketoconazole or itracona</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; zole).</p><p>&nbsp;&nbsp;&nbsp;&nbsp; - Macrolide antibiotics (such as erythromycin or trolean-</p><p>&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;domycin).</p><p>&nbsp;&nbsp;&nbsp;&nbsp; - Antivirals (such as ritonavir).</p><p>&bull; You are taking another drug called cyclosporin (used after transplants to prevent organ rejection)</p><p>&bull; With grapefruit or grapefruit juice</p><p>Do not use if you are pregnant or breastfeeding (see section Pregnancy and Breastfeeding for more information).</p><p><strong>&nbsp;</strong></p><p><strong>Take special care with Lercadip and tell your doctor if:</strong></p><p>&bull; You have certain other heart conditions which have not been treated by insertion of a pacemaker or have pre-existing angina</p><p>&bull; You have problems with your liver or kidneys or you are on dialysis</p><p>&nbsp;</p><p><strong>Using other medicines</strong></p><p>Please tell your doctor or pharmacist if:</p><p>&bull; You are taking or have recently taken any other medicines, including medicines obtained without a prescription</p><p>&bull; You are taking beta-blockers e.g. metoprolol, diuretics (water tablets) or ACE-inhibitors (medicines to treat high blood pressure)</p><p>&bull; You are taking cimetidine (more than 800 mg, a medicine for ulcers, indigestion, or heartburn)</p><p>&bull; You are taking digoxin (a medicine to treat a heart problem)</p><p>&bull; You are taking midazolam (a medicine that helps you sleep)</p><p>&bull; You are taking rifampicin (a medicine to treat tuberculosis)</p><p>&bull; You are taking astemizole or terfenadine (medicines for allergies)</p><p>&bull; You are taking amiodarone or quinidine (medicines to treat a fast heart beat)</p><p>&nbsp;&bull; You are taking phenytoin or carbamazepine (medicines for epilepsy). Your doctor will want to monitor your blood pressure more frequently than usual.</p><p>&nbsp;&bull; Some medicines should <strong>not</strong> be taken at the same time as Lercadip. See section 2 &lsquo;Do not take Lercadip and tell your doctor if:&rsquo; for a list of these.</p><p>&nbsp;</p><p><strong>Taking Lercadip with food and drink</strong></p><p>&bull; Patients should not consume alcohol during treatment with Lercadip tablets since it may increase the effect of Lercadip tablets.</p><p>&bull; Patients should not take grapefruit or grapefruit juice.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breastfeeding</strong></p><p>Do not use Lercadip if you are pregnant or breastfeeding, or you wish to become pregnant or if you are not using any contraceptive method.</p><p>If you are taking Lercadip and think that you may be pregnant, consult your doctor.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Caution should be exercised because of the possibility of dizziness, weakness and tiredness. Do not drive or use machines until you know how Lercadip affects you.</p><p><strong>&nbsp;</strong></p><p><strong>Information about some ingredients of Lercadip:</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, e.g. intolerance to lactose, galactosaemia or glucose/galactose malabsorption syndrome, contact your doctor before taking this medicinal product, as the tablets contain lactose.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Lercadip exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Adults:</strong>&nbsp; The usual dose is 10 mg film coated tablet daily at the same time each day, preferably in the morning at least 15 minutes before breakfast, because a high fat meal significantly increases blood levels of the drug. Your doctor may advise you to increase the dose to one Lercadip 20 mg film coated tablet daily, if needed.</p><p>The tablets should preferably be swallowed whole with some water.</p><p>&nbsp;</p><p><strong>Elderly:</strong>&nbsp; No adjustment of the daily dose is required. However, special care should be exercised in starting treatment.</p><p>&nbsp;</p><p><strong>Patients with liver or kidney problems: </strong>Special care is needed in starting treatment in these patients and an increase in daily dose to 20 mg should be approached with caution.</p><p>&nbsp;</p><p><strong>Children:</strong>&nbsp; This medicine should not be used in children under 18 years of age.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product ask your doctor.</p><p>&nbsp;</p><p><strong>If you take more Lercadip than you should</strong></p><p><strong>Do not exceed the prescribed dose.</strong></p><p>&nbsp;</p><p>If you take more than the prescribed dose or in the event of overdose, seek medical advice immediately and, if possible, take your tablets and/or the container with you.</p><p>&nbsp;</p><p>Exceeding the correct dosage may cause blood pressure to become too low, and the heart to beat irregularly or faster. It may also lead to unconsciousness.</p><p>&nbsp;</p><p><strong>If you forget to take Lercadip</strong></p><p>If you forget to take your tablet, simply miss that dose and then go on as before. Do not take a double dose.</p><p><strong>&nbsp;</strong></p><p><strong>If you stop taking Lercadip</strong></p><p>If you stop taking Lercadip your blood pressure may increase again. Please consult your doctor before stopping the treatment.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Lercadip can cause side effects, although not everybody gets them.</p><p><strong>&nbsp;</strong></p><p><strong>Some side effects can be serious:</strong></p><p>&nbsp;</p><p><strong>If you experience any of these side effects tell your doctor straight away.</strong>&nbsp;</p><p>- Rare (affecting less than 1 out of 1000 patients): angina pectoris (chest pain due to lack of blood to your heart)</p><p>&nbsp;</p><p>- Very rare (affecting less than 1 out of 10,000 patients): chest pain, fall in blood pressure, fainting and allergic reactions (symptoms include itching, rash, hives)</p><p>&nbsp;</p><p>If you suffer from pre-existing angina pectoris, with the group of medicines to which Lercadip belongs, you may experience increased frequency, duration or severity of these attacks. Isolated cases of heart attack may be observed.</p><p>&nbsp;</p><p><strong>Other possible side effects:</strong></p><p>- Uncommon (affecting less than 1 out of 100 patients): headache, dizziness, faster heart beats, palpitations (heart pounding or racing), sudden reddening of the face, neck or upper chest, ankle swelling.</p><p>&nbsp;</p><p>- Rare (affecting less than 1 out of 1000 patients): sleepiness, feeling sick, vomiting, heartburn, stomach pain, diarrhoea, skin rash, muscle pain, passage of large amounts of urine, tiredness.</p><p>&nbsp;</p><p>- Very rare (affecting less than 1 out of 10,000 patients): swelling of gums, changes in liver function (detected by blood tests), increase in the usual number of times one urinates.</p><p><strong>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Keep out of the reach and sight of children</strong></p><p>&nbsp;</p><p>Do not use Lercadip after the expiry date, which is stated on the carton and on blister. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from light and moisture. The original package should be kept in a dry place.</p><p>Medicines should not be disposed of via wastewater of household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is: lercanidipine hydrochloride 10 mg which is equivalent to 9.4 mg of lercanidipine or lercanidipine hydrochloride 20 mg which is equivalent to 18.8 mg of lercanidipine.</p><p>The other ingredients are:</p><p><strong>Core tablet:</strong> lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, povidone K30, magnesium stearate.</p><p>&nbsp;</p><p><strong>Film coating:</strong> hypromellose, talc, titanium dioxide (E171), macrogol 6000 and ferric oxide (E172).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lercadip 10 mg:  yellow, circular, biconvex, film coated tablet scored on one side, engraved “ALG L10” on the other. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Lercadip 20 mg: pink , circular, biconvex, film coated tablet scored on one side, engraved “ALG L20” on the other.

Lercadip is available in blister packs of 7, 14, 28, 30, 35, 42, 50, 56, 98, 100 tablets. Not all pack sizes may be marketed.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Marketing Authorization Holder And Final Batch Releaser</p><p><strong>ALGORITHM S.A.L.</strong> Zouk Mosbeh, Lebanon</p><p>&nbsp;</p><p>Manufacturer</p><p><strong>ALGORITHM S.A.L.</strong> Zouk Mosbeh, Lebanon</p><p>&nbsp;</p><p>Under license from Recordati</p><p>rkaRegistered Tradem<sup> &reg;</sup></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rev. No. 09/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي ليركاديب إلى مجموعة من الأدوية تُسمّى حاصرات قناة الكلسيوم (مشتقّات الديهدروبيريدين). يُستعمل ليركاديب لعلاج ضغط الدم المرتفع المعروف أيضًا بفرط ضغط الدم لدى البالغين الذين يفوق عمرهم 18 عامًا (لا يوصى باستعماله لدى الأفراد ما دون الـ18 من العمر).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ ليركاديب وأعلم الطبيب:</strong></p><p dir="RTL">&bull; إذا كنت تعاني من حساسيّة (فرط حساسيّة) ضدّ ليركانيديبين هيدروكلورايد أو ضدّ أيّ مكوّنات أخرى في أقراص ليركاديب</p><p dir="RTL">&bull; إذا أُصبت في السابق بارتكاسات تحسسيّة ضدّ أدوية تتعلّق تعلقًا وثيقًا بأقراص ليركاديب (مثل أملوديبين، نيكارديبين، فيلوديبين، إسراديبين، نيفيديبين أو لاسيديبين)</p><p dir="RTL">&bull; إذا كنت تعاني من بعض أمراض القلب:</p><p dir="RTL">&nbsp;&nbsp;&nbsp; - قصور قلبي غير معالج</p><p dir="RTL">&nbsp;&nbsp;&nbsp; - انسداد دفق الدم من القلب</p><p dir="RTL">&nbsp;&nbsp;&nbsp; - ذبحة غير ثابتة (ذبحة عند الراحة أو متزايدة تدريجيًا)</p><p dir="RTL">&nbsp;&nbsp;&nbsp; - في غضون شهر واحد بعد التعرّض لنوبة قلبيّة</p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل كبديّة أو كلويّة حادة</p><p dir="RTL">&bull; إذا كنت تأخذ أدوية تثبّط الإنزيم الإسوي CYP3A4:</p><p dir="RTL">&nbsp;&nbsp;&nbsp; - الأدوية المضادة للفطريّات (مثل كيتوكونازول أو إتراكونازول)</p><p dir="RTL">&nbsp;&nbsp;&nbsp; - المضادات الحيويّة من فئة الماكروليد (مثل إيريثرومايسين أو ترولياندومايسين)</p><p dir="RTL">&nbsp;&nbsp;&nbsp; - مضادات الفيروسات (مثل ريتونافير)</p><p dir="RTL">&bull; إذا كنت تأخذ دواء آخر يُدعى سيكلوسبورين (يُستعمل بعد عمليّات الغرس لتفادي رفض الأعضاء)</p><p dir="RTL">&bull; مع الكريب فروت أو عصير الكريب فروت</p><p dir="RTL">لا تستعملي هذا الدواء إذا كنتِ حاملاً أو مرضعة (راجعي فقرة الحمل والإرضاع للمزيد من المعلومات).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إعتمد عناية خاصة مع ليركاديب وأعلم طبيبك:</strong></p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل قلبيّة معيّنة أخرى لم تُعالج عبر إدخال ناظمة&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">قلبيّة أو إذا كان لديك ذبحة موجودة أصلاً.</p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل كبديّة أو كلويّة أو كنت تخضع للديلزة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إستعمال أدوية أخرى</strong></p><p dir="RTL">الرجاء أن تُعلم الطبيب أو الصيدلي:</p><p dir="RTL">&bull; إذا كنت تأخذ حاليًا أو أخذت مؤخّرًا أيّ أدوية أخرى بما فيها تلك التي حصلت عليها بدون وصفة طبيّة</p><p dir="RTL">&bull; إذا كنت تأخذ حاصرات بيتا مثلاً ميتوبرولول، أو مدرّات بول، أو مثبّطات إنزيم تحويل الأنجيوتنسن ACE&nbsp;(أدوية لعلاج ضغط الدم المرتفع)</p><p dir="RTL">&bull; إذا كنت تأخذ سيميتيدين (أكثر من 800 ملغرام، وهو دواء للقرحة، عسر الهضم وحرقة القلب)</p><p dir="RTL">&bull; إذا كنت تأخذ ديغوكسين (دواء يعالج مشكلة قلبيّة)</p><p dir="RTL">&bull; إذا كنت تأخذ ميدازولام (دواء يساعد على النوم)</p><p dir="RTL">&bull; إذا كنت تأخذ ريفامبيسين (دواء لعلاج السلّ)</p><p dir="RTL">&bull; إذا كنت تأخذ أستيميزول أو ترفينادين (دواءان للحساسيّة)</p><p dir="RTL">&bull; إذا كنت تأخذ أميودارون أو كينيدين (دواءان لعلاج دقّات القلب السريعة)</p><p dir="RTL">&bull; إذا كنت تأخذ فينيتوين أو كاربامازيبين (دواءان للصرع). سوف يراقب طبيبك ضغط دمك أكثر من العادة.</p><p dir="RTL">&bull; لا ينبغي أخذ بعض الأدوية في الوقت نفسه مع ليركاديب. راجع الفقرة 2 &laquo; لا تأخذ ليركاديب وأعلم الطبيب&raquo; لتحصل على لائحة هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخذ ليركاديب مع الطعام والشراب</strong></p><p dir="RTL">&bull; لا ينبغي بالمرضى استهلاك الكحول في خلال فترة العلاج بأقراص ليركاديب بما أنّ الكحول قد تزيد من مفعول أقراص ليركاديب.</p><p dir="RTL">&bull; لا ينبغي بالمرضى تناول الكريب فروت أو عصير الكريب فروت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">لا تستعملي أقراص ليركاديب إذا كنتِ حاملاً أو مرضعة أو إذا كنتِ ترغبين بالحمل أو كنتِ لا تستعملين أيّ وسيلة منع حمل.</p><p dir="RTL">إذا كنتِ تأخذين ليركاديب وكنت تعتقدين نفسكِ حاملاً، استشيري طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة السيّارات واستعمال الآلات</strong></p><p dir="RTL">يجب اعتماد الحذر بسبب إحتمال الإصابة بالدوار، بالضعف وبالتعب. لا تقد سيّارة ولا تشغّل آلة إلى أن تعرف كيفيّة تأثير ليركاديب عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات حول بعض مكوّنات ليركاديب:</strong></p><p dir="RTL">إذا قال لك طبيبك إنّك تعاني من عدم تحمّل بعض أنواع السكر أيّ عدم تحمّل اللاكتوز أو من الغلكتوزميّة أو من تناذر سوء امتصاص الغلوكوز/الغلاكتوز، اتصل بطبيبك قبل أخذ هذا الدواء لأنّ الأقراص تحتوي على اللاكتوز.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong>خذ دائمًا ليركاديب حسب وصفة الطبيب تمامًا. يجب عليك التحقق من طبيبك أو من الصيدلي إذا لم تكن متأكّدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون:</strong> تبلغ الجرعة العادية قرصًا واحدًا مطليّ الغشاء من 10 ملغرام يوميًا يُؤخذ في الوقت نفسه كلّ يوم، من المفضّل عند الصباح قبل الفطور بـ15 دقيقة على الأقلّ، لأنّ وجبة تحتوي على كميّة عالية من الدهون تزيد مستويات الدواء في الدم بشكل كبير. قد ينصحك طبيبك بزيادة الجرعة إلى قرص واحد ليركاديب مطليّ الغشاء من 20 ملغرام يوميًا عند الحاجة.</p><p dir="RTL">يُفضّل بلع الأقراص كاملة مع بعض الماء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المسنّون:</strong> ما من حاجة لتعديل الجرعة اليوميّة. ولكن يجب اعتماد عناية خاصة عند بدء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل كبديّة أو كلويّة:</strong> يجب اعتماد عناية خاصة عند بدء العلاج لدى هؤلاء المرضى ويجب مقاربة زيادة الجرعة اليوميّة إلى 20 ملغرام بحذر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأفراد ما دون الـ18 من العمر:</strong> لا ينبغي استعمال هذا الدواء لدى هذه الفئة من العمر.</p><p dir="RTL">إذا كان لديك أيّ أسئلة إضافيّة حول استعمال هذا الدواء إطرحها على طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أخذت كميّة مفرطة من ليركاديب</strong></p><p dir="RTL"><strong>لا تتجاوز الجرعة الموصوفة.</strong></p><p dir="RTL">إذا تخطيت الجرعة الموصوفة أو إذا أخذت جرعة مفرطة، اطلب مساعدة طبيّة على الفور وإذا كان ذلك ممكنًا خذ أقراصك و/أو علبة الدواء معك.</p><p dir="RTL">قد يسبّب تجاوز الجرعة الصحيحة انخفاض ضغط الدم بشكل كبير وعدم انتظام دقّات القلب أو تسارعها. كما قد يسبّب فقدان وعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أخذ ليركاديب</strong></p><p dir="RTL">إذا نسيت أخذ قرصك فوّت الجرعة ببساطة ومن ثمّ عاود أخذ الدواء كالمعتاد. لا تأخذ جرعة مضاعفة .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقّفت عن أخذ ليركاديب </strong></p><p dir="RTL">إذا توقّفت عن أخذ ليركاديب قد يرتفع ضغط دمك مجددًا. الرجاء أن تستشير طبيبك قبل إيقاف العلاج.</p><p dir="RTL">إذا كان لديك أيّ أسئلة إضافيّة حول استعمال هذا الدواء إطرحها على طبيبك أو على الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل الأدوية كلّها قد يسبّب ليركاديب تأثيرات جانبيّة لا تُصيب المرضى كلّهم.</p><p dir="RTL"><strong>يمكن أن تكون بعض التأثيرات الجانبيّة خطيرة:</strong></p><p dir="RTL"><strong>إذا أُصبت بأحد هذه التأثيرات الجانبيّة أعلم طبيبك على الفور. </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">- التأثيرات النادرة (تُصيب أقلّ من مريض من أصل 1000 مريض): ذبحة صدريّة (ألم في الصدر بسبب نقص الدم إلى القلب)</p><p dir="RTL">- التأثيرات النادرة جدًا (تُصيب أقلّ من مريض من أصل 10000 مريض): ألم في الصدر، هبوط ضغط الدم، إغماء وارتكاسات تحسسيّة (تتضمّن العوارض حكّة وطفحًا وشرى)</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من ذبحة صدريّة موجودة أصلاً، قد تصبح هذه النوبات أكثر تواترًا وأطول وقتًا وأكثر حدّة مع مجموعة الأدوية التي ينتمي إليها ليركاديب. يمكن حدوث حالات منعزلة من النوبة القلبيّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبيّة محتملة أخرى:</strong></p><p dir="RTL">- التأثيرات غير الشائعة (تُصيب أقل من مريض من أصل 100 مريض): صداع، دوار، تسارع دقّات القلب، خفقان (خفقان القلب بشدّة أو تسارع دقّاته)، احمرار مفاجئ في الوجه أو العنق أو الجزء الأعلى من الصدر، تورّم الكاحلين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">- التأثيرات النادرة (تُصيب أقلّ من مريض من أصل 1000 مريض): نعاس، غثيان، تقيّؤ، حرقة قلب، ألم معدة، إسهال، طفح جلدي، ألم عضلي، مرور كميّات كبيرة من البول، تعب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">- التأثيرات النادرة جدًا (تُصيب أقلّ من مريض من أصل 10000 مريض): تورّم اللثة، تغييرات في وظيفة الكبد (تُكشف عن طريق فحوصات دم)، زيادة في التبوّل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا تفاقم أحد التأثيرات الجانبيّة أو إذا لاحظت تأثيرات جانبيّة غير مذكورة في هذه النشرة، الرجاء أن تُعلم الطبيب أو الصيدلي. </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>إحفظ الدواء بعيدًا عن متناول الأطفال ونظرهم</strong></p><p dir="RTL">لا تستعمل ليركاديب بعد انقضاء تاريخ الصلاحيّة المدوّن على علبة الكرتون والظرف. يشير تاريخ انتهاء الصلاحيّة إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">يحفظ في درجات حرارة لا تتعدى 30 درجة مئوية.</p><p dir="RTL">إحفظ الدواء في علبته الأصليّة لحمايته من النور والرطوبة. يجب حفظ العلبة الأصليّة في مكان جاف.</p><p dir="RTL">لا ينبغي التخلّص من الأدوية عبر مياه الصرف الصحي أو في النفايات المنزليّة. إسأل الصيدلي عن كيفيّة التخلّص من الأدوية التي لم تعد بحاجة إليها، فمن شأن هذه الإجراءات حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفاعلة هي: ليركانيديبين هيدروكلورايد 10 ملغرام ما يعادل 9.4 ملغرام من الليركانيديبين أو ليركانيديبين هيدروكلورايد 20 ملغرام ما يعادل 18.8 ملغرام من الليركانيديبين.</p><p dir="RTL">المكوّنات الأخرى هي:</p><p dir="RTL"><strong>قلب القرص:</strong> لاكتوز وحيد التميّه، سلولوز دقيق البلوريّة، غليكولات نشا الصوديوم، بوفيدون K30، ستيارات المغنيزيوم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غلاف القرص:</strong> هبروميلوز، طلق، ثاني أكسيد التيتانيوم (E 171)، ماكروغول 6000، أكسيد الحديدي (E 172).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ب.كيف هو شكل ليركاديب ومحتويات العلبة</strong></p><p dir="RTL">ليركاديب 10 ملغرام: قرص أصفر اللون ومستدير وثنائيّ التحدّب ومطليّ الغشاء، قابل للقطع من جهة واحدة ومحفور عليه &ldquo;ALG L10&rdquo; من الجهة الأخرى. خطّ القطع هو لتسهيل الكسر بغية تسهيل البلع فحسب وهو لا يقسم القرص إلى جرعتين متساويتين.</p><p dir="RTL">ليركاديب 20 ملغرام: قرص زهريّ اللون ومستدير وثنائيّ التحدّب ومطليّ&nbsp; الغشاء وهو قابل للقطع من جهة واحدة ومحفور عليه &ldquo;ALG L20&rdquo; من الجهة الأخرى.&nbsp;</p><p dir="RTL">يأتي ليركاديب في علب ظروف من 7، 14، 28، 30، 35، 42، 50، 56، 98، 100 قرص. قد لا تكون أحجام العلب كلّها مسوّقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك رخصة التسويق والمصنع المسؤول عن تحرير الصنف:</p><p dir="RTL"><strong>ألغوريتم ش.م.ل.</strong> ذوق مصبح ، لبنان</p><p dir="RTL">&nbsp;</p><p dir="RTL">الشركة المصنّعة:</p><p dir="RTL"><strong>ألغوريتم ش.م.ل</strong>. ذوق مصبح ، لبنان</p><p dir="RTL">&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_3" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:39pt;height:9pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image001.emz"
  o:title=""/>
</v:shape><![endif]--><img width="52" height="12" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" />&nbsp;&nbsp;&nbsp;&nbsp;بإذن من ريكورداتي</p><p dir="RTL"><sup>م</sup>&nbsp;ماركة مسجلة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LERCADIP  20 mg film-coated tablets  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lercanidipine hydrochloride 20 mg, which is equivalent to 18.8 mg of lercanidipine.  
	 	Excipients: 
	 	Lactose-monohydrate 60 mg 
  
	 	For a full list of excipients, see section 6.1.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.  
	 	Pink, circular, biconvex tablets, scored on one side.  
	 	The tablet can be divided into equal halves. 
  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LERCADIP is indicated in adults for the treatment of mild to moderate essential hypertension.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dosage is 10 mg orally once a day; the dose may be increased to 20 mg depending on the individual patient&#39;s response.&nbsp;</p><p>&nbsp;</p><p>Dose titration should be gradual, because it may take about 2 weeks before the maximal antihypertensive effect is apparent.&nbsp;</p><p>&nbsp;</p><p>Some individuals, not adequately controlled on a single antihypertensive agent, may benefit from the addition of LERCADIP to therapy with a beta-adrenoceptor blocking drug (atenolol), a diuretic (hydrochlorothiazide) or an angiotensin converting enzyme inhibitor (captopril or enalapril).&nbsp;</p><p>&nbsp;</p><p>Since the dose-response curve is steep with a plateau at doses between 20-30 mg, it is unlikely that efficacy will be improved by higher doses; whereas side effects may increase.&nbsp;</p><p><em>&nbsp;</em>&nbsp;</p><p><strong><em>Use in the elderly:</em></strong> although the pharmacokinetic data and clinical experience suggest that no adjustment of the daily dosage is required, special care should be exercised when initiating treatment in the elderly.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>Use in renal or hepatic dysfunction:</em></strong> special care should be exercised when treatment is commenced in patients with mild to moderate<strong> </strong>renal or hepatic dysfunction. Although the usually recommended dose schedule may be tolerated by these subgroups, an increase in dose to 20 mg daily must be approached with caution. The antihypertensive effect may be enhanced in patients with hepatic impairment and consequently an adjustment of the dosage should be considered.&nbsp;</p><p>&nbsp;</p><p>LERCADIP is not recommended for use in patients with severe hepatic impairment or in patients with severe renal impairment (GFR &lt; 30 ml/min).</p><p>&nbsp;</p><p><strong><em>Peadiatric population</em></strong></p><p>The safety and efficacy of LERCADIP in children aged up to 18 years have not been established.</p><p>No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>The tablet should be taken orally once a day at least 15 minutes before meals.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to lercanidipine hydrochloride, to any dihydropyridine or to any of the excipients.  
•	Pregnancy and lactation (see section 4.6).   
•	Women of child-bearing potential unless effective contraception is used (see section 4.6).   
•	Left ventricular outflow tract obstruction.  
•	Untreated congestive cardiac failure.  
•	Unstable angina pectoris.  
•	Severe renal or hepatic impairment.  
•	Within 1 month of a myocardial infarction.  
•	Co-administration with:   
 o strong inhibitors of CYP3A4 (see section 4.5),   o cyclosporin (see section 4.5),   o grapefruit juice (see section 4.5).  
  

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Special care should be exercised when LERCADIP is used in patients with sick sinus syndrome (if a pacemaker is not in situ). Although hemodynamic controlled studies revealed no impairment of ventricular function, care is also required in patients with LV dysfunction. It has been suggested that some short-acting dihydropyridines may be associated with increased cardiovascular risk in patients with ischaemic heart disease. Although LERCADIP is long-acting caution is required in such patients.&nbsp;&nbsp;</p><p>Some dihydropyridines may rarely lead to precordial pain or angina pectoris. Very rarely patients with pre-existing angina pectoris may experience increased frequency, duration or severity of these attacks. Isolated cases of myocardial infarction may be observed (see section 4.8).&nbsp;</p><p>&nbsp;</p><p><strong><em>Use in renal or hepatic dysfunction:</em></strong> special care should be exercised when treatment is commenced in patients with mild to moderate<strong> </strong>renal or hepatic dysfunction. Although the usually recommended dose schedule may be tolerated by these subgroups, an increase in dose to 20 mg daily must be approached with caution. The antihypertensive effect may be enhanced in patients with hepatic impairment and consequently an adjustment of the dosage should be considered.&nbsp;</p><p>LERCADIP is not recommended for use in patients with severe hepatic impairment or in patients with severe renal impairment (GFR &lt; 30 ml/min) (see section 4.2).&nbsp;</p><p>&nbsp;</p><p>Alcohol should be avoided since it may potentiate the effect of vasodilating antihypertensive drugs (see section 4.5).&nbsp;</p><p>&nbsp;</p><p>Inducers of CYP3A4 like anticonvulsants (e.g. phenytoin, carbamazepine) and rifampicin may reduce lercanidipine&rsquo;s plasma levels and therefore the efficacy of lercanidipine may be less than expected&nbsp; (see section 4.5).&nbsp;</p><p>&nbsp;</p><p>1 tablet contains 60 mg lactose and therefore should not be administered to patients with Lapp lactase insufficiency, galactosaemia or glucose/galactose malabsorption syndrome.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>have only been performed in adults.</p><p>Lercanidipine is known to be metabolised by the CYP3A4 enzyme and, therefore, inhibitors and inducers of CYP3A4 administered concurrently may interact with the metabolism and elimination of lercanidipine.&nbsp;</p><p><strong><em>&nbsp;</em></strong>&nbsp;</p><p>Co-prescription of LERCADIP with inhibitors of CYP3A4 (e.g. ketoconazole, itraconazole, ritonavir, erythromycin, troleandomycin) should be avoided (see section 4.3).&nbsp;</p><p>An interaction study with a strong CYP3A4 inhibitor, ketoconazole, has shown a considerable increase in plasma levels of lercanidipine (a 15-fold increase of the AUC and an 8-fold increase of the C for the eutomer S-lercanidipine). <em>&nbsp;</em>&nbsp;max</p><p><em>&nbsp;</em>&nbsp;</p><p>Cyclosporin and lercanidipine should not be administered together (see section 4.3).&nbsp;</p><p>Increased plasma levels of both lercanidipine and cyclosporin have been observed following concomitant administration. A study in young healthy volunteers has shown that when cyclosporin was administered 3 hours after the lercanidipine intake, the plasma levels of lercanidipine did not change, while the AUC of cyclosporin increased by 27%. However, the co-administration of LERCADIP with cyclosporin has caused a 3-fold increase of the plasma levels of lercanidipine and a 21% increase of the cyclosporin AUC.&nbsp;&nbsp;</p><p>&nbsp;</p><p>Lercanidipine should not be taken with grapefruit juice (see section 4.3).&nbsp;</p><p>As for other dihydropyridines, lercanidipine is sensitive to inhibition of metabolism by grapefruit juice, with a consequent rise in its systemic availability and increased hypotensive effect.&nbsp;&nbsp;</p><p>&nbsp;</p><p>When concomitantly administered at a dose of 20 mg with midazolam p.o. to elderly volunteers, lercanidipine&rsquo;s absorption was increased (by approximately 40%) and the rate of absorption was decreased (t was delayed from 1.75 to 3 hours). Midazolam max</p><p>concentrations were not modified.&nbsp;</p><p>&nbsp;</p><p>Caution should be exercised when LERCADIP is co-prescribed with other substrates of CYP3A4, like terfenadine, astemizole, class III antiarrhythmic drugs such as amiodarone, quinidine.&nbsp;&nbsp;</p><p>&nbsp;</p><p>Co-administration of LERCADIP with CYP3A4 inducers like anticonvulsants (e.g. phenytoin, carbamazepine) and rifampicin should be approached with caution since the antihypertensive effect may be reduced and blood pressure should be monitored more frequently than usual.&nbsp;&nbsp;</p><p>&nbsp;</p><p>When LERCADIP was co-administered with metoprolol, a &beta;-blocker eliminated mainly by the liver, the bioavailability of metoprolol was not changed while that of lercanidipine was reduced by 50%. This effect may be due to the reduction in the hepatic blood flow caused by &beta;-blockers and may therefore occur with other drugs of this class. Consequently, lercanidipine may be safely administered with beta-adrenoceptor blocking drugs, but dose adjustment may be required.&nbsp;</p><p>&nbsp;</p><p>An interaction study with fluoxetine (an inhibitor of CYP2D6 and CYP3A4), conducted in volunteers of an age of 65 &plusmn; 7 years (mean &plusmn; s.d.), has shown no clinically relevant modification of the pharmacokinetics of lercanidipine.&nbsp;</p><p><em>&nbsp;</em>&nbsp;</p><p>Concomitant administration of cimetidine 800 mg daily does not cause significant modifications in plasma levels of lercanidipine, but at higher doses caution is required since the bioavailability and the hypotensive effect of lercanidipine may be increased.&nbsp;</p><p>&nbsp;</p><p>Co-administration of 20 mg lercanidipine<strong><em> </em></strong>in patients chronically treated with&nbsp; &beta;methyldigoxin showed no evidence of pharmacokinetic interaction. Healthy volunteers treated with digoxin following dosing with 20 mg lercanidipine given fasted showed a mean increase of 33% in digoxin C , while AUC and renal<em> </em>clearance were not significantly max</p><p>modified. Patients on concomitant digoxin treatment should be closely monitored clinically for signs of digoxin toxicity.&nbsp;</p><p>&nbsp;</p><p>When a dose of 20 mg of LERCADIP was repeatedly co-administered with 40 mg of simvastatin, the AUC of lercanidipine was not significantly modified, while simvastatin&rsquo;s AUC increased by 56% and that of its active metabolite &beta;-hydroxyacid by 28%. It is unlikely that such changes are of clinical relevance. No interaction is expected when lercanidipine is administered in the morning and simvastatin in the evening, as indicated for such drug.&nbsp;&nbsp;</p><p>&nbsp;</p><p>The co-administration of 20 mg lercanidipine to healthy volunteers given fasted did &nbsp;not alter the pharmacokinetics of warfarin.&nbsp;</p><p>&nbsp;</p><p>LERCADIP has been safely administered with diuretics and ACE inhibitors.&nbsp;</p><p><strong><em>&nbsp;</em></strong>&nbsp;</p><p>Alcohol should be avoided since it may potentiate the effect of vasodilating antihypertensive drugs (see section 4.4).&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in males and females</u></p><p>Data for lercanidipine provide no evidence of a teratogenic effect in the rat and the rabbit and reproductive performance in the rat was unimpaired. Nevertheless, since there is no clinical experience with lercanidipine in pregnancy and lactation, and other dihydropyridine compounds have been found teratogenic in animals.</p><p>LERCADIP should not be administered in&nbsp; women with child-bearing potential unless effective contraception is used.&nbsp;</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;There are no or limited amount of data from the use of lercanidipine in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3).&nbsp;</p><p>&nbsp; LERCADIP is not recommended during pregnancy and in women with child-bearing</p><p>potential not using contraception.&nbsp;</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>&nbsp;&nbsp; &nbsp;It is unknown whether lercanidipine/metabolites are excreted in human milk. A risk in the&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;newborns/infants cannot be excluded. LERCADIP is contraindicated during&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breastfeeding (see section 4.3)&nbsp;</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No clinical data are available with lercanidipine. Reversible biochemical changes in the head&nbsp; of spermatozoa which can impair fecundation have been reported in some patients treated by&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; channel blockers. In cases where repeated in-vitro fertilization is unsuccessful and where&nbsp; &nbsp;&nbsp; another explanation cannot be found, the possibility of calcium channel blockers as the cause&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; should be considered</p><p>&nbsp;</p><p><strong>&nbsp;</strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LERCADIP has minor influence on the ability to drive and use machines, because dizziness, asthenia, fatigue and rarely somnolence may occur.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>About 1.8% of treated patients experienced adverse reactions.&nbsp;</p><p>The table below shows the incidence of adverse drug reactions, at least possibly causally related, grouped by MedDRA System Organ Class classification and&nbsp; frequency: : very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (frequency cannot be estimated from available data). Within each frequency grouping the observed adverse reactions are presented in order of decreasing seriousness.&nbsp;</p><p>&nbsp;</p><p>As shown in the table, the most commonly occurring adverse drug reactions reported in controlled clinical trials are headache, dizziness, peripheral oedema, tachycardia, palpitations, flushing, each occurring in less than 1% of patients. &nbsp;</p><p>&nbsp;Spontaneous reports from the post-marketing experience are grouped under the &ldquo;not</p><p>known&rdquo; frequency category.</p><p>&nbsp;&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:579px"><tbody><tr><td style="vertical-align:top"><p>MedDRA</p><p>System Organ Class</p></td><td style="vertical-align:top"><p>Uncommon</p><p>(&ge;1/1,000 to</p><p>1/100)</p></td><td style="vertical-align:top"><p>Rare</p><p>(&ge;1/10,000 to</p><p>&lt;1/1,000)</p></td><td><p>Very rare (&lt;1/10,000)</p></td><td><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Immune System</p><p>Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous System Disorders</p></td><td style="vertical-align:top"><p>dizziness headache;&nbsp;</p></td><td style="vertical-align:top"><p>somnolence</p></td><td style="vertical-align:top"><p>Syncope&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac Disorders</p></td><td style="vertical-align:top"><p>tachycardia; palpitations</p></td><td style="vertical-align:top"><p>angina pectoris</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular Disorders</p></td><td style="vertical-align:top"><p>flushing</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abdominal pain, vomiting, nausea; dyspepsia; diarrhoea&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>gingival hypertrophy</p></td></tr><tr><td style="vertical-align:top"><p>Skin and</p><p>Subcutaneous</p><p>Tissue Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>rash</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal,</p><p>Connective</p><p>Tissue&nbsp;&nbsp;</p><p>Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and</p><p>Urinary</p><p>Disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>polyuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>urinary frequency</p></td></tr><tr><td style="vertical-align:top"><p>General</p><p>Disorders and</p><p>Administration</p><p>Site Conditions</p></td><td style="vertical-align:top"><p>oedema</p><p>peripheral</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>asthenia; fatigue</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>chest pain</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>transaminases increased</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>Some dihydropyridines may lead to precordial pain or angina pectoris. Patients with preexisting angina pectoris may experience increased frequency, duration or severity of these attacks.&nbsp; Cases of myocardial infarction may be observed.<em> </em>&nbsp;</p><p>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lercanidipine does not appear to influence&nbsp; blood sugar or serum lipid levels.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the post-marketing experience,&nbsp; some cases of overdose were reported (from 40 up to&nbsp; 800 mg of lercanidipine,including reports of&nbsp; suicide attempt).&nbsp;</p><p>&nbsp;</p><p>As with other dihydropyridines, overdosage might be expected to cause excessive peripheral vasodilatation. Symptoms associated to overdose include&nbsp; marked hypotension,&nbsp; dizziness, fatigue and reflex tachycardia. Cardiac failure, myocardial ischaemia and acute renal failure might occur. In case of severe hypotension cardiovascular support could be helpful.&nbsp;</p><p>&nbsp;</p><p>In view of the prolonged pharmacological effect of lercanidipine, it is essential that the cardiovascular status of patients who take an overdose is monitored for 24 hours at least. There is no information on the value of dialysis. Since the drug is highly lipophilic, it is most probable that plasma levels are no guide to the duration of the period of risk and dialysis may not be effective.&nbsp;</p><p><strong>&nbsp;</strong>&nbsp;</p><p><strong>&nbsp;</strong>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:&nbsp;&nbsp;</p><p>Dihydropyridine derivatives.</p><p>ATC code: C08CA13&nbsp;</p><p>&nbsp;</p><p><strong><em>Mechanism of action </em></strong></p><p>Lercanidipine is a calcium antagonist of the dihydropyridine group and inhibits the transmembrane influx of calcium into cardiac and smooth muscle. The mechanism of its antihypertensive action is due to a direct relaxant effect on vascular smooth muscle thus lowering total peripheral resistance.</p><p>&nbsp;</p><p><strong><em>Pharmacodynamics effects </em></strong></p><p>Despite its short pharmacokinetic plasma half-life, lercanidipine is endowed with a prolonged antihypertensive activity because of its high membrane partition coefficient, and is devoid of negative inotropic effects due to its high vascular selectivity.&nbsp;</p><p>Since the vasodilatation induced by LERCADIP is gradual in onset, acute hypotension with reflex tachycardia has rarely been observed in hypertensive patients.&nbsp;&nbsp;</p><p>As for other asymmetric 1,4-dihydropyridines, the antihypertensive activity of lercanidipine is mainly due to its (S)-enantiomer.&nbsp;</p><p>&nbsp;</p><p><strong><em>Clinical efficacy and safety </em></strong></p><p>In addition to the clinical studies conducted to support the therapeutic indications, a further small uncontrolled but randomised study of patients with severe hypertension (mean <u>+</u> SD diastolic blood pressure of 114.5 <u>+</u> 3.7 mmHg) showed that blood pressure was normalized in 40% of the 25 patients on 20 mg once daily dose and in 56% of 25 patients on 10 mg twice daily doses of LERCADIP. In a double-blind, randomized, controlled study versus placebo in patients with isolated systolic hypertension LERCADIP was efficacious in lowering systolic blood pressure from mean initial values of 172.6 <u>+</u> 5.6&nbsp; mmHg to 140.2 <u>+</u>&nbsp;8.7 mmHg.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LERCADIP is completely absorbed after 10-20 mg oral administration and peak plasma levels, 3.30 ng/ml <u>+</u> 2.09 s.d. and 7.66 ng/ml <u>+</u> 5.90 s.d. respectively, occur about 1.5-3 hours after dosing.&nbsp;</p><p>The two enantiomers of lercanidipine show a similar plasma level profile: the time to peak plasma concentration is the same, the peak plasma concentration and AUC are, on average, 1.2-fold higher for the (S) enantiomer and the elimination half-lives of the two enantiomers are essentially the same. No &quot;in vivo&quot; interconversion of enantiomers is observed.&nbsp;</p><p>Due to the high first pass metabolism, the absolute bioavailability of LERCADIP orally administered to patients under fed conditions is around 10%, although it is reduced to 1/3 when administered to healthy volunteers under fasting conditions.&nbsp;</p><p>Oral availability of lercanidipine increases 4-fold when LERCADIP is ingested up to 2 hours after a high fat meal. Accordingly, LERCADIP should be taken before meals.&nbsp;</p><p>&nbsp;</p><p><strong><em>Distribution</em></strong>:</p><p>Distribution from plasma to tissues and organs is rapid and extensive.&nbsp;</p><p>The degree of serum protein binding of lercanidipine exceeds 98%. Since plasma protein levels are reduced in patients with severe renal or hepatic dysfunction, the free fraction of the drug may be increased.&nbsp;</p><p><em>&nbsp;</em>&nbsp;</p><p><strong><em>Biotransformation</em></strong>:</p><p>LERCADIP is extensively metabolised by CYP3A4; no parent drug is found in the urine or the faeces. It is predominantly converted to inactive metabolites and about 50% of the dose is excreted in the urine.&nbsp;</p><p>&nbsp;</p><p><em>&ldquo;In vitro&rdquo;</em> experiments with human liver microsomes have demonstrated that lercanidipine shows some degree of inhibition of CYP3A4 and CYP2D6, at concentrations 160- and 40fold, respectively, higher than those reached at peak in the plasma after the dose of 20 mg.&nbsp;</p><p>&nbsp;</p><p>Moreover, interaction studies in humans have shown that lercanidipine did not modify the plasma levels of midazolam, a typical substrate of CYP3A4, or of metoprolol, a typical substrate of CYP2D6. Therefore, inhibition of biotransformation of drugs metabolised by CYP3A4 and CYP2D6 by LERCADIP is not expected at therapeutic doses.&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong><em>Elimination</em></strong>:</p><p>Elimination occurs essentially by biotransformation<strong>.&nbsp; </strong>&nbsp;</p><p>A mean terminal elimination half life of 8-10 hours was calculated and the therapeutical activity lasts for 24 hours because of its high binding to lipid membrane. No accumulation was seen upon repeated administration.&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong><em>Linearitry/non linearity</em></strong>:</p><p>Oral administration of LERCADIP leads to plasma levels of lercanidipine not directly proportional to dosage (non-linear kinetics). After 10, 20 or 40 mg, peak plasma concentrations observed were in the ratio 1:3:8 and areas under plasma concentration-time curves in the ratio 1:4:18, suggesting a progressive saturation of first pass metabolism. Accordingly, availability increases with dosage elevation.&nbsp;</p><p>&nbsp;</p><p><strong><em>Characteristics in special patients</em></strong>:</p><p>In elderly patients and in patients with mild to moderate renal dysfunction or mild to moderate hepatic impairment the pharmacokinetic behaviour of lercanidipine was shown to be similar to that observed in the general patient population; patients with severe renal dysfunction or dialysis-dependent patients showed higher levels (about 70%) of the drug. In patients with moderate to severe hepatic impairment, the systemic bioavailability of lercanidipine is likely to be increased since the drug is normally metabolised extensively in the liver.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction.&nbsp;</p><p>Safety pharmacological studies in animals have shown no effects on the autonomic nervous system, the central nervous system or on gastrointestinal function at antihypertensive doses.<strong><em> </em></strong>&nbsp;</p><p>&nbsp;</p><p>The relevant effects which have been observed in long-term studies in rats and dogs were related, directly or indirectly, to the known effects of high doses of Ca-antagonists, predominantly reflecting exaggerated pharmacodynamic activity.&nbsp;</p><p>&nbsp;</p><p>Lercanidipine was not genotoxic and showed no evidence of carcinogenic hazard.<strong><em> </em></strong>&nbsp;</p><p><strong><em>&nbsp;</em></strong>&nbsp;</p><p>Fertility and general reproductive performance in rats were unaffected by treatment with lercanidipine.&nbsp;</p><p><strong><em>&nbsp;</em></strong>&nbsp;</p><p>There was no evidence of any teratogenic effect in rats and rabbits; however, in rats, lercanidipine at high dose levels induced pre- and post- implantation losses and delay in foetal development.&nbsp;</p><p>&nbsp;</p><p>Lercanidipine hydrochloride, when administered at high dose (12 mg/kg/day) during labour, induced dystocia.&nbsp;</p><p>&nbsp;</p><p>The distribution of lercanidipine and/or its metabolites in pregnant animals and their excretion in breast milk have not been investigated.</p><p>&nbsp;</p><p>Metabolites have not been evaluated separately in toxicity studies.&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:&nbsp;&nbsp;</p><p>Lactose monohydrate&nbsp;&nbsp;</p><p>Microcrystalline cellulose&nbsp;&nbsp;</p><p>Sodium starch glycolate&nbsp;&nbsp;</p><p>Povidone K30&nbsp;</p><p>Magnesium stearate&nbsp;</p><p>&nbsp;</p><p>Film coating:&nbsp;&nbsp;</p><p>Hypromellose&nbsp;&nbsp;</p><p>Talc&nbsp;&nbsp;</p><p>Titanium dioxide (E171)&nbsp;&nbsp;</p><p>Macrogol 6000&nbsp;</p><p>Ferric oxide (E172)&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.&nbsp;</p><p><strong>&nbsp;</strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.  
  

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;&nbsp; Store in a dry place below 30&deg;C, protected from light. Do not refrigerate. Store in the original package.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/opaque PVC blisters.&nbsp;</p><p>Pack of 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Algorithm S.A.L, lebanon 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2012 
  

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>